Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Ocular Therapeutix Progresses Phase 3 OTX-TKI Trial
Ocular Therapeutix has announced that over 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). This marks a critical milestone in the development of the first registrational trial for OTX-TKI as a…
EyePoint Begins Phase 3 LUCIA Trial for Wet AMD
EyePoint Pharmaceuticals has successfully dosed the first patient in the LUCIA trial, marking the start of the company’s second global Phase 3 clinical study for Duravyu (formerly EYP-1901), an investigational sustained-release therapy for wet age-related macular degeneration (wet AMD). Duravyu:…
ARPA-H Grants $125M for Eye Transplants
The Advanced Research Projects Agency for Health (ARPA-H) has announced funding of up to $125 million to support groundbreaking research into human eye transplantation. The funding, part of the Transplantation of Human Eye Allografts (THEA) program, aims to advance the…
Nicox Completes Denali Phase 3 Enrollment
Nicox has announced the completion of patient enrollment in China for the Denali Phase 3 trial, which evaluates the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension. The screening process in China is now…
EPOMEC 2024: Ophthalmology Conference Highlights
The Evolving Practice of Ophthalmology Middle East Conference (EPOMEC) is set to take place from December 5–7, 2024, at the Dubai World Trade Centre, United Arab Emirates. This prestigious event brings together the latest advancements in ophthalmology from across the…
Vision-restoring whole eye transplants may soon be a reality – Stanford Medicine
Vision-restoring whole eye transplants may soon be a reality Stanford Medicine Source: Author: | Date: 2024-12-02 21:30:00 Source: Author: | Date: 2024-12-02 21:30:00
Prevent Blindness Offers GA Educational Materials
Prevent Blindness, a leading nonprofit organization dedicated to eye health, has announced its fourth annual Geographic Atrophy (GA) Awareness Week, taking place from December 2–8, 2024. Geographic Atrophy, an advanced form of dry age-related macular degeneration (AMD), affects an estimated…
AI-Ready Dataset Released for Type 2 Diabetes Research
A groundbreaking study has unveiled a flagship dataset designed to explore the biomarkers and environmental influences that contribute to the development of type 2 diabetes (T2D). This comprehensive dataset includes data from participants ranging from healthy individuals to those at…
ONS-5010 Falls Short in NORSE EIGHT Trial for Wet AMD
ONS-5010 (LYTENAVA), an ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (AMD), failed to meet the noninferiority endpoint in the NORSE EIGHT clinical trial, according to preliminary topline results announced by Outlook Therapeutics. About the NORSE EIGHT Trial…
Gene Editing Offers Hope for Retinitis Pigmentosa
Researchers funded by the National Eye Institute (NEI) have made significant strides in the treatment of retinitis pigmentosa (RP), a genetic disorder that causes progressive vision loss. Using a CRISPR-Cas9-based tool called base editing, the team corrected a specific mutation…